FDA
-
-
-
-
-
-
-
JanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024
-
-
-
-
-
-
-
JanOne to Acquire ALT 5 Sigma Inc., a Leading Next Generation Blockchain Financial Technology Provider
-
-
-
-
-
-
-
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain
-
-
-
-
-
-
-
JanOne (JAN) Completes Pre-IND Meeting with FDA on Jan123
-
-
-
-
-
-
-
JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market
-
-
-
-
-
-
-
JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC
-
-
-
-
-
-
-
JanOne Inc. Acquires an Option for the Rights to a Worldwide, Exclusive License for a Novel Strategy for Treating Methamphetamine Use Disorder
-
323,085 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

